卡培他滨联合干扰素-α抑制裸鼠肝癌生长的实验研究

Capecitabine Combined with Interferon - alpha Inhibited the Growth of Hepatocellular Carcinoma in Nude Mice

目的:研究卡培他滨联合干扰素-α抑制肝癌生长的作用及其机制。方法:人肝癌高转移裸鼠模型LCI—D20 30只,随机分为对照组、卡培他滨组、干扰素组和联合用药组。用药3周后,观察肝内原位瘤体积的变化,利用ELISA方法检测肿瘤组织内的胸苷磷酸化酶(TP)表达水平。结果:对照组、卡培他滨组、干扰素组和联合用药组肿瘤体积分别为1033±146mm^3、455±236mm^3、248±114mm^3和46±29mm^3。与对照组肿瘤体积相比,给药组肿瘤体积明显缩小,联合用药组尤为突出,差异极显著(P<0.01)。析因设计方差分析表明联合应用卡培他滨与干扰素具有协同作用。应用干扰素组(包括干扰素组与联合用药组)与未用干扰素组(包括对照组与卡培他滨组),肿瘤组织中TP酶表达水平分别为30.52±10.73ng/mg蛋白质20.10±3.67ng/mg蛋白质,两组差异极显著(P<0.01)。结论:干扰素-α可上调肝癌组织中TP酶表达,与卡培他滨联合应用具有协同抑制LCI—D20肝癌生长的作用。

Objective: To investigate the effect of capecitabine combined with interferon - alpha and the relevant mechanism. Methods; Nude mice bearing orthotopic xenografty highly metastatic human HCC (LCI - D20) were randomly divided into four groups; control, capecitabine group, interferon group and combination group. The effect on the tumor growth was evalu-ated using tumor volume. An enzyme - linked immunosorbent assay (ELISA) was used to determine thymidine phosphorylase (TP) expression of liver cancer tissue. Results; Interferon - alpha enhanced the sensitivity of LCI - D20 tumor to capecitabine. The tumor volume was 1033 ± 146 mm3,455 ± 236 mm3,248 ±114 mm3and 46 ± 29 mm3 in control, capecitabine group, interferon group and combination group, respectively. The tumor volume significantly decreased in treatment groups compared with control (p<0.01). Interferon - alpha enhanced TP expression in LCI -D20 tumor. About 1. 5 - fold increase in TP expression was observed in administration of interferon - alpha groups compared with that in unuse of interferon - alpha groups.Conclusion: Interferon - alpha upregulated TP expression of liver cancer tissue. There was synergistic action between interferon - alpha and capecitabine in inhibiting the growth of HCC in nude mice.